Trial Profile
A study for apatinib combined with biweekly oxaliplatin and S-1(SOX) as first-line therapy in patients with advanced stomach or gastro esophageal junction cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Oct 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Gimeracil/oteracil/tegafur; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 22 Oct 2018 New trial record